総説 悪性腫瘍の最先端
（2）分子生物学的手法と病理診断
2018 年 88 巻 2 号 p. 43-50
詳細
2018 年 88 巻 2 号 p. 43-50
Understanding the genomic landscape of malignant tumors has revealed novel diagnostic, prognostic, and predictive molecular biomarkers to refine their pathological classifications. However, it remains a major challenge to incorporate molecular genetic information into the routine diagnostics of cancer to achieve "Precision Medicine." Significant progress towards this goal has been achieved owing to the new World Health Organization (WHO) 2016 Classification of Tumors of the Central Nervous System which has enabled traditional histology-based diagnostics to be replaced with a multi-layered approach that combines histologic features and molecular information in an "integrated diagnosis." Described here are state-of-the-art pathological diagnostic approaches using molecular markers for malignant tumors, focusing particularly on brain tumors, which are likely to help ensure more precise diagnostics for personalized medicine.
